Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer weekly round up for August 16th - August 22nd, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 16th - August 22nd, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Current state of prostate cancer in Antigua and Barbuda

Dr Adrian Rhudd - Mount St. John’s Medical Centre, Antigua, Antigua and Barbuda

Current state of prostate cancer in Antigua and Barbuda ( Dr Adrian Rhudd - Mount St. John’s Medical Centre, Antigua, Antigua and Barbuda )

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Patterns of recurrence after a radical nephroureterectomy in high-risk upper...

Dr Alberto Martini - Vita-Salute San Raffaele University, Milan, Italy

Patterns of recurrence after a radical nephroureterectomy in high-risk upper tract urothelial carcinoma ( Dr Alberto Martini - Vita-Salute San Raffaele University, Milan, Italy )

OncoAlert and ecancer weekly round up for July 19 - July 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for July 19 - July 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Part 1: When to test

PARP inhibition in the treatment of prostate cancer

Part 1: When to test ( PARP inhibition in the treatment of prostate cancer )

Part 2: Who to test

PARP inhibition in the treatment of prostate cancer

Part 2: Who to test ( PARP inhibition in the treatment of prostate cancer )

Part 3: How to test

PARP inhibition in the treatment of prostate cancer

Part 3: How to test ( PARP inhibition in the treatment of prostate cancer )

Part 4: Metastatic prostate cancer and HRR defects

PARP inhibition in the treatment of prostate cancer

Part 4: Metastatic prostate cancer and HRR defects ( PARP inhibition in the treatment of prostate cancer )

Part 5: BRCA 1/2 mutations and prostate cancer

PARP inhibition in the treatment of prostate cancer

Part 5: BRCA 1/2 mutations and prostate cancer ( PARP inhibition in the treatment of prostate cancer )

More from ecancer